国际皮肤性病学杂志    2005 31 (1): 35-37   ISSN: 2096-5540  CN: 32-1880/R   细胞因子与硬皮病的研究进展 晋松, 吕昭萍 昆明医学院第一附属医院皮肤科 650032 收稿日期 2004-04-23  修回日期 null  网络版发布日期 null 参考文献  [1] Riccieri V, Rinaldi T, Spadaro A, et al. Interleukin-13 in systemic sclerosis:relationship to nailfold capillaroscopy abnormalities. Clin Rheumatol, 2003,22:102-106. [2] Kurasawa K, Hirose K, Sano H, et al. Increased interleukin-17 production in patients with systemic sclerosis. Arthritis Rheum,2000,43:2455-2463. [3] Choi JJ, Min DJ, Cho ML, et al. Elevated vascular endothelial growth factor in systemic sclerosis. J Rheumatol, 2003,30:1529-1533. [4] Distler O, Del Rosso A, Giacomelli R, et al. Angiogenic and angiostatic factors in systemic sclerosis:increased levels of vascular endothelial growth factor are a feature of the earliest disease stages and are associated with the absence of fingertip ulcers. Arthritis Res, 2002,4:R1 1. [5] Tsuji-Yamada J, Nakazawa M, Minami M, et al. Increased frequency of interleukin 4 producing CD4 + and CD8 + cells in peripheral blood from patients with systemic sclerosis. J Rheumatol,2001,28 :12528. [6] Neiko IeM, Iatsyshyn RI. Role of interleukin-1 and interleukin-2 in the pathogenesis of systemic scleroderma. Fiziol Zh, 2002,48:56-61. [7] Yamamoto T, Eckes B, Krieg T. High expression and autoinduction of monocyte chemoattractant protein-1 in scleroderma fibroblasts. Eur J Immunol, 2001,31:2936-2941. [8] Distler O, Pap T, Kowal-Bielecka O, et al. Overexpression of monocyte chemoattractant protein 1 in systemic sclerosis:role of plateletderived growth factor and effects on monocyte chemotaxis and collagen synthesis. Arthritis Rheum,2001,44:2665-2678. [9] Postiglione L, Montagnani S, Riccio A, et al. Enhanced expression of the receptor for granulocyte macrophage colony stimulating factor on dermal fibroblasts from scleroderma patients. J Rheumatol, 2002,29:94-101. [10] Ihn H. The role of TGF-beta signaling in the pathogenesis of fibrosis in scleroderma. Arch Immunol Ther Exp (Warsz), 2002,50:325. [11] Susol E, Rands AL, Herrick A, et al. Association of markers for TGFbeta3, TGFbeta2 and TIMP1 with systemic sclerosis. Rheumatology (Oxford), 2000,39:1332-1336. [12] Mori Y, Chen SJ, Varga J. Expression and regulation of intracellular SMAD signaling in scleroderma skin fibroblasts. Arthritis Rheum,2003, 48:1964-1978. [13] Sato M, Shegogue D, Gore EA, et al. Role of p38 MAPK in transforming growth factor beta stimulation of collagen production by scleroderma and healthy dermal fibroblasts. J Invest Dermatol, 2002,118:704. [14] Leask A, Holmes A, Abraham DJ. Connective tissue growth factor:a new and important player in the pathogenesis of fibrosis. Curr Rheumatol Rep, 2002,4:136-142. [15] Sato S, Hasegawa M, Takehara K. Serum levels of interleukin-6 and interleukin-10 correlate with total skin thickness score in patients with systemic sclerosis. J Dermatol Sci, 2001,27:140-146. [16] Murota H, Hamasaki Y, Nakashima T, et al. Disruption of tumor necrosis factor receptor p55 impairs collagen turnover in experimentally induced sclerodermic skin fibroblasts. Arthritis Rheum, 2003, 48:1117-1125. [17] Mouthon L, Garcia De La Pena-Lefebvre P, Chanseaud Y, et al.Pathogenesis of systemic scleroderma:immunological aspects. Ann Med Interne (Paris), 2002,153:167-178. [18] Martinez JA, Nishimura C, Guatura SR, et al. Elevation of soluble interleukin-2 receptor levels in the bronchoalveolar lavage from patients with systemic sclerosis. Rheumatol Int, 2001,21:122-126. [19] Furuse S, Fujii H, Kaburagi Y, et al. Serum concentrations of the CXC chemokines interleukin 8 and growth-regulated oncogene-alpha are elevated in patients with systemic sclerosis. J Rheumatol, 2003,30:1524-1528. [20] Sato S, Hanakawa H, Hasegawa M, et al. Levels of interleukin 12, a cytokine of type 1 helper T cells, are elevated in sera from patients with systemic sclerosis. J Rheumatol, 2000,27:2838-2842. [21] Suzuki J, Morimoto S, Amano H, et al. Serum levels of interleukin 15 in patients with rheumatic diseases. J Rheumatol,2001,28 :2389. [22] Matucci-Cerinic M, Giacomelli R, Pignone A, et al. Nerve growth factor and neuropeptides circulating levels in systemic sclerosis (scleroderma). Ann Rheum Dis, 2001,60:487-494. [23] Kawaguchi Y, Harigai M, Hara M, et al. Expression of hepatocyte growth factor and its receptor (c-met) in skin fibroblasts from patients with systemic sclerosis. J Rheumatol, 2002, 29:1877-1883. 通讯作者: